Apalutamide, as a second-generation high-selectivity androgen receptor antagonist, has an affinity for the androgen receptor more than 5 times that of first-generation drugs and is widely used in the treatment of non-metastatic castration-resistant prostate cancer; the APADX version produced by Lao BigBear Pharma provides a new compliant option in this field.
How much does Lao BigBear version of Apalutamide cost?
The Lao BigBear version of Apalutamide is available in a specification of 60mg*120 tablets/box, with a price of approximately $130. The specific price may be affected by various factors and is subject to the actual selling price.
Drug interactions of Apalutamide and their clinical significance
Apalutamide is a potent CYP3A4 inducer, and also induces CYP2C19 and CYP2C9, and can affect the activity of UGT, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1). Therefore, when co-administered with sensitive substrate drugs that rely on these metabolic enzymes or transporters for clearance, it may lead to a significant decrease in the plasma concentration of the substrate drugs, thereby losing efficacy. Typical affected drugs include: warfarin (CYP2C9 substrate) – increased INR monitoring frequency required; clopidogrel (CYP2C19 prodrug) – may reduce active metabolite generation, increasing thrombosis risk; statins (OATP1B1 substrates, e.g., atorvastatin) – attenuated lipid-lowering effect; digoxin (P-gp substrate) – decreased blood concentration, requiring adjustment of cardiac glycoside dosage; oral contraceptives (hormonal, CYP3A4 substrates) – increased risk of contraceptive failure, and it is recommended that male patients with female partners of reproductive potential use non-hormonal contraceptive measures. In addition, when apalutamide is co-administered with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), although the change in apalutamide exposure is limited, caution is still needed for toxicity accumulation; co-administration with potent inducers (e.g., rifampicin, phenytoin) may further reduce apalutamide efficacy and is not recommended. All concomitant medications should be comprehensively reviewed by a pharmacist before treatment, and alternative drugs or therapeutic drug monitoring should be considered.
Apalutamide use in special populations and storage
Males of reproductive potential: Apalutamide may impair spermatogenesis and embryo-fetal development; therefore, during treatment and for at least 3 months after discontinuation, male patients who have sexual intercourse with female partners of childbearing potential must use both barrier contraception (condoms) in combination with highly effective contraceptive measures (e.g., intrauterine devices or hormonal contraception, but note that the efficacy of hormonal contraceptives may be reduced). Breastfeeding women are not recommended to handle crushed tablets, as the drug can be absorbed through the skin. Hepatic impairment: No initial dose adjustment is required for mild to moderate impairment (Child-Pugh A/B), but data for severe impairment are lacking, so use with caution. Renal impairment: No adjustment is needed for mild to severe renal impairment (including end-stage renal disease), as the drug is mainly metabolized by the liver and excreted in feces. Elderly patients (≥65 years) have safety data similar to younger populations, but more attention should be paid to falls and cardiovascular events. Storage requirements: The drug should be kept in the original bottle, do not discard the desiccant (silica gel), and store at 20°C~25°C (68°F~77°F) at room temperature, protected from light and moisture, with brief excursions permitted to 15°C~30°C (59°F~86°F). Expired or leftover drugs should be disposed of according to local regulations (e.g., FDA guidance) through drug take-back programs, and never flushed down the drain or disposed of in household trash to prevent environmental contamination and accidental exposure.
